Enanta Pharmaceuticals
ENTA
ENTA
195 hedge funds and large institutions have $1.7B invested in Enanta Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 73 increasing their positions, 59 reducing their positions, and 15 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
195
Holders Change
+12
Holders Change %
+6.56%
% of All Funds
4.23%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
29
Increased
73
Reduced
59
Closed
15
Calls
$5.14M
Puts
$7.51M
Net Calls
-$2.38M
Net Calls Change
-$2.51M
Top Buyers
| 1 |
1
T. Rowe Price Associates
Baltimore,
Maryland
|
$131M |
| 2 |
2
Ameriprise
Minneapolis,
Minnesota
|
$48.7M |
| 3 |
3
Citadel Advisors
Miami,
Florida
|
$23.9M |
| 4 |
O
4
OrbiMed
New York
|
$22.3M |
| 5 |
MWNA
5
Marshall Wace North America
New York
|
$21.6M |
Top Sellers
| 1 |
1
Renaissance Technologies
New York
|
$61.7M |
| 2 |
AC
2
Armistice Capital
New York
|
$35.5M |
| 3 |
3
Morgan Stanley
New York
|
$7.42M |
| 4 |
GPP
4
Great Point Partners
Greenwich,
Connecticut
|
$0 |
| 5 |
5
Goldman Sachs
New York
|
$13.8M |
